![]() |
|
|
Vol. 30, Issue 11, 1206-1213, November 2002
XenoTech, LLC, Lenexa, Kansas (R.A.G., A.D., D.M., L.K., K.C.,
A.M., A.P.), and WIL Research Laboratories, Inc., Ashland, Ohio (C.C.)
The aim of this study was to determine the in vitro and in vivo
effects of several prototypical inducers, namely
-naphthoflavone, 3-methylcholanthrene, phenobarbital, isoniazid, rifampin, and clofibric
acid, on the expression of cytochrome P450 (P450) enzymes in
beagle dogs. For the in vitro induction study, primary cultures of dog
hepatocytes were treated with enzyme inducers for 3 days, after which
microsomes were prepared and analyzed for P450 activities. For the in
vivo induction study, male and female beagle dogs were treated with
enzyme inducers for 4 days (with the exception of phenobarbital, which
was given for 14 days), after which the livers were removed and
microsomal P450 activities were determined ex vivo. Treatment of male
beagle dog hepatocyte cultures (n = 3) with
-naphthoflavone or 3-methlychloranthrene resulted in up to a 75-fold
increase in microsomal 7-ethoxyresorufin O-dealkylase (CYP1A1/2) activity, whereas in vivo treatment of male and female beagle dogs with
-naphthoflavone followed by ex vivo analysis resulted in up to a 24-fold increase. Phenobarbital caused a 13-fold increase in 7-benzyloxyresorufin O-dealkylase (CYP2B11)
activity in vitro and up to a 9.9-fold increase in vivo. Isoniazid had little or no effect on 4-nitrophenol hydroxylase activity in vitro. Rifampin caused a 13-fold induction of testosterone 6
-hydroxylase (CYP3A12) activity in vitro and up to a 4.5-fold increase in vivo. Treatment of dogs in vivo or dog hepatocytes in vitro with clofibric acid appeared to have no effect on CYP4A activity as determined by the
12-hydroxylation of lauric acid. In general, the absolute rates
(picomoles per minute per milligram of microsomal protein) of P450
reactions catalyzed by microsomes from cultured hepatocytes (i.e., in
vitro rates) were considerably lower than those catalyzed by microsomes
from dog liver (i.e., ex vivo rates). These results suggest that beagle
dogs have CYP1A, CYP2B, CYP2E, and CYP3A enzymes and that the induction
profile resembles the profile observed in humans more than in rats.
This article has been cited by other articles:
![]() |
M. Mise, T. Hashizume, and S. Komuro Characterization of Substrate Specificity of Dog CYP1A2 Using CYP1A2-Deficient and Wild-Type Dog Liver Microsomes Drug Metab. Dispos., September 1, 2008; 36(9): 1903 - 1908. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Graham, B. Goodwin, R. V. Merrihew, W. L. Krol, and E. L. LeCluyse Cloning, Tissue Expression, and Regulation of Beagle Dog CYP4A Genes Toxicol. Sci., August 1, 2006; 92(2): 356 - 367. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. R. Gibson, C. Lin, R. Singh, C. M. Brown, K. Richards, J. Brunner, K. Michel, J. Adelsberger, E. Carlini, C. Boothe-Genthe, et al. INDUCTION OF CYP1A IN THE BEAGLE DOG BY AN INHIBITOR OF KINASE INSERT DOMAIN-CONTAINING RECEPTOR: DIFFERENTIAL EFFECTS IN VITRO AND IN VIVO ON MRNA AND FUNCTIONAL ACTIVITY Drug Metab. Dispos., July 1, 2005; 33(7): 1044 - 1051. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Mise, S. Yadera, M. Matsuda, T. Hashizume, S. Matsumoto, Y. Terauchi, and T. Fujii POLYMORPHIC EXPRESSION OF CYP1A2 LEADING TO INTERINDIVIDUAL VARIABILITY IN METABOLISM OF A NOVEL BENZODIAZEPINE RECEPTOR PARTIAL INVERSE AGONIST IN DOGS Drug Metab. Dispos., February 1, 2004; 32(2): 240 - 245. [Abstract] [Full Text] [PDF] |
||||